Gene therapy associated uveitis mechanisms and modulation in animal models

Kathryn People, MD, PhD

Associate Professor, Ophthalmology

Division Director, Uveitis

Director of Clinical Research

Director Uveitis Fellowship

University of Washington

Learning Objectives:
1. Introduce AAV mediated gene therapy as an important emerging treatment modality for a range of blinding eye diseases. 2.Understand the clinical concern of gene therapy associated uveitis (GTAU) in patients receiving AAV mediated ocular gene therapy. 3. Review innate and adaptive immune responses underlying GTAU. 4. Describe treatment options and pre-clinical evidence for targeting T cells to prevent GTAU.

Disclosures:

Dr. Pepple reports financial relationship as a consultant for Roche/Genentech and Astellas Pharmaceuticals, and a financial relationship as a data safety monitoring board member for Janssen Research and Development.

Dr. Subramanian reports financial relationship as a consultant for ACELYRIN, Alexion Pharma, Amgen, GenSight Biologics, Invex Therapeutics, Kriya Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, an investigator for Amgen, GenSight Biologics, Immunovant, Invex Therapeutics, Neurophth Therapeutics and Viridian Therapeutics, recipient of a research grant from Amgen and a DSMB member for Argenx, Dr. Ertel reports financial relationships as a consultant for New World Medical and Allergan. All of the other planners, faculty, or individuals in control of content for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

The University of Colorado School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Colorado School of Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.